These results indicate that blocking the interactions of immune checkpoint molecules, PD-1/PD-L1 or CTLA4/CD80/CD86 interactions, together with TKIs is effective at eliminating human CML LSCs in the presence of T cell immunity. Here, CD86 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.